Forbion (Group)

https://www.forbion.com

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio)pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 69 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. *

	Start	2006-12-01 splitoff
	Today	Forbion Capital Partners (NL)
	Predecessor	ABN AMRO Capital Life Sciences
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Slootweg, Sander (Forbion Capital Partners 20111 Managing Partner before ABN AMRO Capital)
	Person 2	Kersten, Dirk (Forbion 201810– General Partner before Inkef Capital + Gilde Healthcare)

	Region	Naarden
	Country	Netherlands
	Street	2-35 Gooimeer
	City	1411 DC Naarden
	Tel	+31-35-699-3000
		Address record changed: 2021-04-24

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	1,700,000,000 (capital under management (2021) 2021-03-01)

		* Document for ï¿½About Sectionï¿½: Forbion Capital Partners. (4/16/21). "Press Release: Forbion Appoints Head of Communications". Amsterdam.

		Record changed: 2021-07-14